Samen werken, voor een psychisch gezonde jeugd

Zoeken
Generic filters
Exact matches only

Bronnen

Anagnostou E. (2018). Clinical trials in autism spectrum disorder: evidence, challenges and future directions. Current opinion in neurology31(2), 119–125. https://doi.org/10.1097/WCO.0000000000000542

van Andel, D. M., Sprengers, J. J., Oranje, B., Scheepers, F. E., Jansen, F. E., & Bruining, H. (2020). Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study. Molecular autism11(1), 30. https://doi.org/10.1186/s13229-020-00335-4

Anderson, L. T., Campbell, M., Grega, D. M., Perry, R., Small, A. M., & Green, W. H. (1984). Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. The American journal of psychiatry141(10), 1195–1202. https://doi.org/10.1176/ajp.141.10.1195

Aman, M. G., Arnold, L. E., McDougle, C. J., Vitiello, B., Scahill, L., Davies, M., McCracken, J. T., Tierney, E., Nash, P. L., Posey, D. J., Chuang, S., Martin, A., Shah, B., Gonzalez, N. M., Swiezy, N. B., Ritz, L., Koenig, K., McGough, J., Ghuman, J. K., & Lindsay, R. L. (2005). Acute and long-term safety and tolerability of risperidone in children with autism. Journal of child and adolescent psychopharmacology15(6), 869–884. https://doi.org/10.1089/cap.2005.15.869

Aman, M. G., Hollway, J. A., McDougle, C. J., Scahill, L., Tierney, E., McCracken, J. T., Arnold, L. E., Vitiello, B., Ritz, L., Gavaletz, A., Cronin, P., Swiezy, N., Wheeler, C., Koenig, K., Ghuman, J. K., & Posey, D. J. (2008). Cognitive effects of risperidone in children with autism and irritable behavior. Journal of child and adolescent psychopharmacology18(3), 227–236. https://doi.org/10.1089/cap.2007.0133

Aman, M. G., McDougle, C. J., Scahill, L., Handen, B., Arnold, L. E., Johnson, C., Stigler, K. A., Bearss, K., Butter, E., Swiezy, N. B., Sukhodolsky, D. D., Ramadan, Y., Pozdol, S. L., Nikolov, R., Lecavalier, L., Kohn, A. E., Koenig, K., Hollway, J. A., Korzekwa, P., Gavaletz, A., … Research Units on Pediatric Psychopharmacology Autism Network (2009). Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry48(12), 1143–1154. https://doi.org/10.1097/CHI.0b013e3181bfd669

Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. American journal of mental deficiency89(5), 485–491.

Arnold, L. E., Aman, M. G., Cook, A. M., Witwer, A. N., Hall, K. L., Thompson, S., & Ramadan, Y. (2006). Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. Journal of the American Academy of Child and Adolescent Psychiatry45(10), 1196–1205. https://doi.org/10.1097/01.chi.0000231976.28719.2a

Arnold, L. E., Vitiello, B., McDougle, C., Scahill, L., Shah, B., Gonzalez, N. M., Chuang, S., Davies, M., Hollway, J., Aman, M. G., Cronin, P., Koenig, K., Kohn, A. E., McMahon, D. J., & Tierney, E. (2003). Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. Journal of the American Academy of Child and Adolescent Psychiatry42(12), 1443–1450. https://doi.org/10.1097/00004583-200312000-00011

Belsito, K. M., Law, P. A., Kirk, K. S., Landa, R. J., & Zimmerman, A. W. (2001). Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. Journal of autism and developmental disorders31(2), 175–181. https://doi.org/10.1023/a:1010799115457

Bolman, W. M., & Richmond, J. A. (1999). A double-blind, placebo-controlled, crossover pilot trial of low dose dimethylglycine in patients with autistic disorder. Journal of autism and developmental disorders29(3), 191–194. https://doi.org/10.1023/a:1023023820671

Bruining, H., Hardstone, R., Juarez-Martinez, E.L. et al. (2020). Measurement of excitation-inhibition ratio in autism spectrum disorder using critical brain dynamics. Sci Rep, 10, 9195. https://doi.org/10.1038/s41598-020-65500-4

Bruining, H., Passtoors, L., Goriounova, N., Jansen, F., Hakvoort, B., de Jonge, M., & Poil, S. S. (2015). Paradoxical Benzodiazepine Response: A Rationale for Bumetanide in Neurodevelopmental Disorders?. Pediatrics136(2), e539–e543. https://doi.org/10.1542/peds.2014-4133

Buitelaar, J. K., & Willemsen-Swinkels, S. H. (2000). Medication treatment in subjects with autistic spectrum disorders. European child & adolescent psychiatry9 Suppl 1, I85–I97. https://doi.org/10.1007/s007870070022

Campbell, M., Armenteros, J. L., Malone, R. P., Adams, P. B., Eisenberg, Z. W., & Overall, J. E. (1997). Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. Journal of the American Academy of Child and Adolescent Psychiatry36(6), 835–843. https://doi.org/10.1097/00004583-199706000-00022

Campbell, M., Anderson, L. T., Small, A. M., Perry, R., Green, W. H., & Caplan, R. (1982). The effects of haloperidol on learning and behavior in autistic children. Journal of autism and developmental disorders12(2), 167–175. https://doi.org/10.1007/BF01531306

Campbell, M., Fish, B., Shapiro, T., & Floyd, A., Jr (1971). Imipramine in preschool autistic and schizophrenic children. Journal of autism and childhood schizophrenia1(3), 267–282. https://doi.org/10.1007/BF01557348

Chugani, D. C., Chugani, H. T., Wiznitzer, M., Parikh, S., Evans, P. A., Hansen, R. L., Nass, R., Janisse, J. J., Dixon-Thomas, P., Behen, M., Rothermel, R., Parker, J. S., Kumar, A., Muzik, O., Edwards, D. J., Hirtz, D., & Autism Center of Excellence Network (2016). Efficacy of Low-Dose Buspirone for Restricted and Repetitive Behavior in Young Children with Autism Spectrum Disorder: A Randomized Trial. The Journal of pediatrics170, 45–53.e534. https://doi.org/10.1016/j.jpeds.2015.11.033

Cooper, W. O., Callahan, S. T., Shintani, A., Fuchs, D. C., Shelton, R. C., Dudley, J. A., Graves, A. J., & Ray, W. A. (2014). Antidepressants and suicide attempts in children. Pediatrics133(2), 204–210. https://doi.org/10.1542/peds.2013-0923

Correll, C. U., Manu, P., Olshanskiy, V., Napolitano, B., Kane, J. M., & Malhotra, A. K. (2009). Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA302(16), 1765–1773. https://doi.org/10.1001/jama.2009.1549

Corson, A. H., Barkenbus, J. E., Posey, D. J., Stigler, K. A., & McDougle, C. J. (2004). A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. The Journal of clinical psychiatry65(11), 1531–1536. https://doi.org/10.4088/jcp.v65n1115

DeLong, G.R., Ritch, C.R., & Burch, S. (2002). Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement. Developmental Medical Child Neurology, 44, 652-659.

Di Martino, A., & Tuchman, R.F. (2001). Antiepileptic drugs: affective use in autism spectrum disorders. Pediatric Neurology, 25, 199-207.

Fankhauser, M. P., Karumanchi, V. C., German, M. L., Yates, A., & Karumanchi, S. D. (1992). A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. The Journal of clinical psychiatry53(3), 77–82.

Findling, R. L., McNamara, N. K., Gracious, B. L., O’Riordan, M. A., Reed, M. D., Demeter, C., & Blumer, J. L. (2004). Quetiapine in nine youths with autistic disorder. Journal of child and adolescent psychopharmacology14(2), 287–294. https://doi.org/10.1089/1044546041649129

Frazier, T. W., Youngstrom, E. A., Haycook, T., Sinoff, A., Dimitriou, F., Knapp, J., & Sinclair, L. (2010). Effectiveness of medication combined with intensive behavioral intervention for reducing aggression in youth with autism spectrum disorder. Journal of child and adolescent psychopharmacology20(3), 167–177. https://doi.org/10.1089/cap.2009.0048

Fuentes, J., Hervás, A. & Howlin, P. (2020) ESCAP practice guidance for autism: a summary of evidence-based recommendations for diagnosis and treatment. Eur Child Adolesc Psychiatry. https://doi.org/10.1007/s00787-020-01587-4

Gadow, K. D., Brown, N. V., Arnold, L. E., Buchan-Page, K. A., Bukstein, O. G., Butter, E., Farmer, C. A., Findling, R. L., Kolko, D. J., Molina, B. S., Rice, R. R., Jr, Schneider, J., & Aman, M. G. (2016). Severely Aggressive Children Receiving Stimulant Medication Versus Stimulant and Risperidone: 12-Month Follow-Up of the TOSCA Trial. Journal of the American Academy of Child and Adolescent Psychiatry55(6), 469–478. https://doi.org/10.1016/j.jaac.2016.03.014

Gencer, O., Emiroglu, F. N., Miral, S., Baykara, B., Baykara, A., & Dirik, E. (2008). Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. An open label maintenance study. European child & adolescent psychiatry17(4), 217–225. https://doi.org/10.1007/s00787-007-0656-6

Goel, R., Hong, J.S., Findling, R.L., et al. (2018). An update on pharmacotherapy of autism spectrum disorder in children and adolescents. International Review of Psychiatry, 30:1, 78-95.

Gordon N. (2000). The therapeutics of melatonin: a paediatric perspective. Brain & development22(4), 213–217. https://doi.org/10.1016/s0387-7604(00)00120-0

Handen, B.L., Johnson, C.R., & Lubetsky, M. (2000). Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. Journal of Autism and Developmental Disorders, 30, 245-255. https://doi.org/10.1023/A:1005548619694

Harfterkamp, M., van de Loo-Neus, G., Minderaa, R. B., van der Gaag, R. J., Escobar, R., Schacht, A., Pamulapati, S., Buitelaar, J. K., & Hoekstra, P. J. (2012). A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry51(7), 733–741. https://doi.org/10.1016/j.jaac.2012.04.011

Hollander, E., Kaplan, A., Cartwright, C., & Reichman, D. (2000). Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report. Journal of child neurology15(2), 132–135. https://doi.org/10.1177/088307380001500214

Hollander, E., Phillips, A., Chaplin, W., Zagursky, K., Novotny, S., Wasserman, S., & Iyengar, R. (2005). A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology30(3), 582–589. https://doi.org/10.1038/sj.npp.1300627

Hollander, E., Wasserman, S., Swanson, E. N., Chaplin, W., Schapiro, M. L., Zagursky, K., & Novotny, S. (2006). A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. Journal of child and adolescent psychopharmacology16(5), 541–548. https://doi.org/10.1089/cap.2006.16.541

Hollander, E., Soorya, L., Wasserman, S., Esposito, K., Chaplin, W., & Anagnostou, E. (2006). Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. The international journal of neuropsychopharmacology9(2), 209–213. https://doi.org/10.1017/S1461145705005791

Jahromi, L. B., Kasari, C. L., McCracken, J. T., Lee, L. S., Aman, M. G., McDougle, C. J., Scahill, L., Tierney, E., Arnold, L. E., Vitiello, B., Ritz, L., Witwer, A., Kustan, E., Ghuman, J., & Posey, D. J. (2009). Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. Journal of autism and developmental disorders39(3), 395–404. https://doi.org/10.1007/s10803-008-0636-9

Jaselskis, C. A., Cook, E. H., Jr, Fletcher, K. E., & Leventhal, B. L. (1992). Clonidine treatment of hyperactive and impulsive children with autistic disorder. Journal of clinical psychopharmacology12(5), 322–327.

Kay, S. R., Wolkenfeld, F., & Murrill, L. M. (1988). Profiles of aggression among psychiatric patients. I. Nature and prevalence. The Journal of nervous and mental disease176(9), 539–546. https://doi.org/10.1097/00005053-198809000-00007 Nederlandse vertaling: Buitelaar, J.

Kemner, C., Willemsen-Swinkels, S. H., de Jonge, M., Tuynman-Qua, H., & van Engeland, H. (2002). Open-label study of olanzapine in children with pervasive developmental disorder. Journal of clinical psychopharmacology22(5), 455–460. https://doi.org/10.1097/00004714-200210000-00003

Kent, J. M., Kushner, S., Ning, X., Karcher, K., Ness, S., Aman, M., Singh, J., & Hough, D. (2013). Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study. Journal of autism and developmental disorders43(8), 1773–1783. https://doi.org/10.1007/s10803-012-1723-5

Kern, J. K., Miller, V. S., Cauller, P. L., Kendall, P. R., Mehta, P. J., & Dodd, M. (2001). Effectiveness of N,N-dimethylglycine in autism and pervasive developmental disorder. Journal of child neurology16(3), 169–173. https://doi.org/10.1177/088307380101600303

Kharod, S. C., Kang, S. K., & Kadam, S. D. (2019). Off-Label Use of Bumetanide for Brain Disorders: An Overview. Frontiers in neuroscience13, 310. https://doi.org/10.3389/fnins.2019.00310

King, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., Bregman, J. D., Donnelly, C. L., Anagnostou, E., Dukes, K., Sullivan, L., Hirtz, D., Wagner, A., Ritz, L., & STAART Psychopharmacology Network (2009). Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Archives of general psychiatry66(6), 583–590. https://doi.org/10.1001/archgenpsychiatry.2009.30

King, B. H., Wright, D. M., Handen, B. L., Sikich, L., Zimmerman, A. W., McMahon, W., Cantwell, E., Davanzo, P. A., Dourish, C. T., Dykens, E. M., Hooper, S. R., Jaselskis, C. A., Leventhal, B. L., Levitt, J., Lord, C., Lubetsky, M. J., Myers, S. M., Ozonoff, S., Shah, B. G., Snape, M., … Cook, E. H., Jr (2001). Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry40(6), 658–665. https://doi.org/10.1097/00004583-200106000-00010

Kolevzon, A., Mathewson, K. A., & Hollander, E. (2006). Selective serotonin reuptake inhibitors in autism: a review of efficacy and tolerability. The Journal of clinical psychiatry67(3), 407–414. https://doi.org/10.4088/jcp.v67n0311

Lahuis, B.E., Ketelaars, C., Troost, P.W., & Buitelaar, J.K. (2008). Autisme en psychofarmaca. In: R. Didden & B. Huskens (Red.), Begeleiding van kinderen en jongeren met autisme. Van onderzoek naar praktijk (pp. 272-289). Bohn Stafleu van Loghum.

Levy S. E. (2002). Repeated doses of porcine secretin did not improve symptoms, language, or cognitive functioning in children with autism or autism spectrum disorder. Evidence-based mental health5(1), 22. https://doi.org/10.1136/ebmh.5.1.22

Malone, R. P., Cater, J., Sheikh, R. M., Choudhury, M. S., & Delaney, M. A. (2001). Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. Journal of the American Academy of Child and Adolescent Psychiatry40(8), 887–894. https://doi.org/10.1097/00004583-200108000-00009

Malone, R. P., Delaney, M. A., Hyman, S. B., & Cater, J. R. (2007). Ziprasidone in adolescents with autism: an open-label pilot study. Journal of child and adolescent psychopharmacology17(6), 779–790. https://doi.org/10.1089/cap.2006.0126

Martin, A., Koenig, K., Anderson, G. M., & Scahill, L. (2003). Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study. Journal of autism and developmental disorders33(1), 77–85. https://doi.org/10.1023/a:1022234605695

Martin, A., Koenig, K., Scahill, L., & Bregman, J. (1999). Open-label quetiapine in the treatment of children and adolescents with autistic disorder. Journal of child and adolescent psychopharmacology9(2), 99–107. https://doi.org/10.1089/cap.1999.9.99

McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., McDougle, C. J., Posey, D., Swiezy, N., Kohn, A., Scahill, L., Martin, A., Koenig, K., Volkmar, F., Carroll, D., Lancor, A., … Research Units on Pediatric Psychopharmacology Autism Network (2002). Risperidone in children with autism and serious behavioral problems. The New England journal of medicine347(5), 314–321. https://doi.org/10.1056/NEJMoa013171

McDougle, C. J., Kem, D. L., & Posey, D. J. (2002). Case series: use of ziprasidone for maladaptive symptoms in youths with autism. Journal of the American Academy of Child and Adolescent Psychiatry41(8), 921–927. https://doi.org/10.1097/00004583-200208000-00010

McDougle, C. J., Kresch, L. E., & Posey, D. J. (2000). Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. Journal of autism and developmental disorders30(5), 427–435. https://doi.org/10.1023/a:1005551523657

McDougle, C. J., Scahill, L., Aman, M. G., McCracken, J. T., Tierney, E., Davies, M., Arnold, L. E., Posey, D. J., Martin, A., Ghuman, J. K., Shah, B., Chuang, S. Z., Swiezy, N. B., Gonzalez, N. M., Hollway, J., Koenig, K., McGough, J. J., Ritz, L., & Vitiello, B. (2005). Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. The American journal of psychiatry162(6), 1142–1148. https://doi.org/10.1176/appi.ajp.162.6.1142

McDougle, C. J., Stigler, K. A., Erickson, C. A., & Posey, D. J. (2008). Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. The Journal of clinical psychiatry69 Suppl 4, 15–20.

McPheeters, M. L., Warren, Z., Sathe, N., Bruzek, J. L., Krishnaswami, S., Jerome, R. N., & Veenstra-Vanderweele, J. (2011). A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics127(5), e1312–e1321. https://doi.org/10.1542/peds.2011-0427

Mehta, U. C., Patel, I., & Castello, F. V. (2004). EEG sedation for children with autism. Journal of developmental and behavioral pediatrics : JDBP25(2), 102–104. https://doi.org/10.1097/00004703-200404000-00005

Miral, S., Gencer, O., Inal-Emiroglu, F. N., Baykara, B., Baykara, A., & Dirik, E. (2008). Risperidone versus haloperidol in children and adolescents with AD : a randomized, controlled, double-blind trial. European child & adolescent psychiatry17(1), 1–8. https://doi.org/10.1007/s00787-007-0620-5

Mohammadi, M. R., Yadegari, N., Hassanzadeh, E., Farokhnia, M., Yekehtaz, H., Mirshafiee, O., & Akhondzadeh, S. (2013). Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study. Clinical neuropharmacology36(6), 179–184. https://doi.org/10.1097/WNF.0b013e3182a9339d

Namerow, L., Thomas, P., Bostic, J. Q., Prince, J., & Monuteaux, M. C. (2003). Use of citalopram in pervasive developmental disorders. Journal of developmental and behavioral pediatrics : JDBP24(2), 104–108. https://doi.org/10.1097/00004703-200304000-00005

Naruse, H., Nagahata, M., Nakane, Y., Shirahashi, K., Takesada, M., & Yamazaki, K. (1982). A multi-center double-blind trial of pimozide (Orap), haloperidol and placebo in children with behavioral disorders, using crossover design. Acta paedopsychiatrica48(4), 173–184.

Owley, T., McMahon, W., Cook, E. H., Laulhere, T., South, M., Mays, L. Z., Shernoff, E. S., Lainhart, J., Modahl, C. B., Corsello, C., Ozonoff, S., Risi, S., Lord, C., Leventhal, B. L., & Filipek, P. A. (2001). Multisite, double-blind, placebo-controlled trial of porcine secretin in autism. Journal of the American Academy of Child and Adolescent Psychiatry40(11), 1293–1299. https://doi.org/10.1097/00004583-200111000-00009

Paavonen, E. J., Nieminen-von Wendt, T., Vanhala, R., Aronen, E. T., & von Wendt, L. (2003). Effectiveness of melatonin in the treatment of sleep disturbances in children with Asperger disorder. Journal of child and adolescent psychopharmacology13(1), 83–95. https://doi.org/10.1089/104454603321666225

Pandina, G. J., Bossie, C. A., Youssef, E., Zhu, Y., & Dunbar, F. (2007). Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. Journal of autism and developmental disorders37(2), 367–373. https://doi.org/10.1007/s10803-006-0234-7

Parikh, M. S., Kolevzon, A., & Hollander, E. (2008). Psychopharmacology of aggression in children and adolescents with autism: a critical review of efficacy and tolerability. Journal of child and adolescent psychopharmacology18(2), 157–178. https://doi.org/10.1089/cap.2007.0041

Pearson, D. A., Santos, C. W., Aman, M. G., Arnold, L. E., Casat, C. D., Mansour, R., Lane, D. M., Loveland, K. A., Bukstein, O. G., Jerger, S. W., Factor, P., Vanwoerden, S., Perez, E., & Cleveland, L. A. (2013). Effects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms. Journal of child and adolescent psychopharmacology23(5), 337–351. https://doi.org/10.1089/cap.2012.0096

Politte, L. C., Scahill, L., Figueroa, J., McCracken, J. T., King, B., & McDougle, C. J. (2018). A randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: an analysis of secondary outcome measures. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology43(8), 1772–1778. https://doi.org/10.1038/s41386-018-0039-3

Posey, D. J., Aman, M. G., McCracken, J. T., Scahill, L., Tierney, E., Arnold, L. E., Vitiello, B., Chuang, S. Z., Davies, M., Ramadan, Y., Witwer, A. N., Swiezy, N. B., Cronin, P., Shah, B., Carroll, D. H., Young, C., Wheeler, C., & McDougle, C. J. (2007). Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. Biological psychiatry61(4), 538–544. https://doi.org/10.1016/j.biopsych.2006.09.028

Posey, D. J., Guenin, K. D., Kohn, A. E., Swiezy, N. B., & McDougle, C. J. (2001). A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. Journal of child and adolescent psychopharmacology11(3), 267–277. https://doi.org/10.1089/10445460152595586

Posey, D. J., Wiegand, R. E., Wilkerson, J., Maynard, M., Stigler, K. A., & McDougle, C. J. (2006). Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. Journal of child and adolescent psychopharmacology16(5), 599–610. https://doi.org/10.1089/cap.2006.16.599

Potenza, M. N., Holmes, J. P., Kanes, S. J., & McDougle, C. J. (1999). Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. Journal of clinical psychopharmacology19(1), 37–44. https://doi.org/10.1097/00004714-199902000-00008

Quintana, H., Birmaher, B., Stedge, D., Lennon, S., Freed, J., Bridge, J., & Greenhill, L. (1995). Use of methylphenidate in the treatment of children with autistic disorder. Journal of autism and developmental disorders25(3), 283–294. https://doi.org/10.1007/BF02179289

Ray, W. A., Stein, C. M., Murray, K. T., Fuchs, D. C., Patrick, S. W., Daugherty, J., Hall, K., & Cooper, W. O. (2019). Association of Antipsychotic Treatment With Risk of Unexpected Death Among Children and Youths. JAMA psychiatry76(2), 162–171. https://doi.org/10.1001/jamapsychiatry.2018.3421

Reed, V. A., Buitelaar, J. K., Anand, E., Day, K. A., Treuer, T., Upadhyaya, H. P., Coghill, D. R., Kryzhanovskaya, L. A., & Savill, N. C. (2016). The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research. CNS drugs30(7), 603–628. https://doi.org/10.1007/s40263-016-0349-0

Remington, G., Sloman, L., Konstantareas, M., Parker, K., & Gow, R. (2001). Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. Journal of clinical psychopharmacology21(4), 440–444. https://doi.org/10.1097/00004714-200108000-00012

Roy, A., Roy, M., Deb, S., Unwin, G., & Roy, A. (2015). Are opioid antagonists effective in attenuating the core symptoms of autism spectrum conditions in children: a systematic review. Journal of intellectual disability research : JIDR59(4), 293–306. https://doi.org/10.1111/jir.12122

Satterstrom, F. K., Kosmicki, J. A., Wang, J., Breen, M. S., De Rubeis, S., An, J. Y., Peng, M., Collins, R., Grove, J., Klei, L., Stevens, C., Reichert, J., Mulhern, M. S., Artomov, M., Gerges, S., Sheppard, B., Xu, X., Bhaduri, A., Norman, U., Brand, H., … Buxbaum, J. D. (2020). Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of Autism. Cell180(3), 568–584.e23. https://doi.org/10.1016/j.cell.2019.12.036

Scahill, L., Riddle, M. A., McSwiggin-Hardin, M., Ort, S. I., King, R. A., Goodman, W. K., Cicchetti, D., & Leckman, J. F. (1997). Children’s Yale-Brown Obsessive Compulsive Scale: reliability and validity. Journal of the American Academy of Child and Adolescent Psychiatry36(6), 844–852. https://doi.org/10.1097/00004583-199706000-00023

Scahill, L., McCracken, J. T., King, B. H., Rockhill, C., Shah, B., Politte, L., Sanders, R., Minjarez, M., Cowen, J., Mullett, J., Page, C., Ward, D., Deng, Y., Loo, S., Dziura, J., McDougle, C. J., & Research Units on Pediatric Psychopharmacology Autism Network (2015). Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder. The American journal of psychiatry172(12), 1197–1206. https://doi.org/10.1176/appi.ajp.2015.15010055

Schulte, J. T., Wierenga, C. J., & Bruining, H. (2018). Chloride transporters and GABA polarity in developmental, neurological and psychiatric conditions. Neuroscience and biobehavioral reviews90, 260–271. https://doi.org/10.1016/j.neubiorev.2018.05.001

Shea, S., Turgay, A., Carroll, A., Schulz, M., Orlik, H., Smith, I. et al. (2004). Risperidon in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114, e634-e641.

Sinzig, J., Döpfner, M., Lehmkuhl, G., German Methylphenidate Study Group, Uebel, H., Schmeck, K., Poustka, F., Gerber, W. D., Günter, M., Knölker, U., Gehrke, M., Hässler, F., Resch, F., Brünger, M., Ose, C., & Fischer, R. (2007). Long-acting methylphenidate has an effect on aggressive behavior in children with attention-deficit/hyperactivity disorder. Journal of child and adolescent psychopharmacology17(4), 421–432. https://doi.org/10.1089/cap.2007.0011

Smith, T., Aman, M. G., Arnold, L. E., Silverman, L. B., Lecavalier, L., Hollway, J., Tumuluru, R., Hyman, S. L., Buchan-Page, K. A., Hellings, J., Rice, R. R., Jr, Brown, N. V., Pan, X., & Handen, B. L. (2016). Atomoxetine and Parent Training for Children With Autism and Attention-Deficit/Hyperactivity Disorder: A 24-Week Extension Study. Journal of the American Academy of Child and Adolescent Psychiatry55(10), 868–876.e2. https://doi.org/10.1016/j.jaac.2016.06.015

Sprengers, J. J., van Andel, D. M., Zuithoff, N., Keijzer-Veen, M. G., Schulp, A., Scheepers, F. E., Lilien, M. R., Oranje, B., & Bruining, H. (2020). Bumetanide for Core Symptoms of Autism Spectrum Disorder (BAMBI): A Single Center, Double-Blinded, Participant-Randomized, Placebo-Controlled, Phase-2 Superiority Trial. Journal of the American Academy of Child and Adolescent Psychiatry, S0890-8567(20)31290-9. Advance online publication. https://doi.org/10.1016/j.jaac.2020.07.888

Stepanova, E., Dowling, S., Phelps, M., & Findling, R. L. (2017). Pharmacotherapy of emotional and behavioral symptoms associated with autism spectrum disorder in children and adolescents. Dialogues in clinical neuroscience19(4), 395–402. https://doi.org/10.31887/DCNS.2017.19.4/rfindling

Stigler, K. A., Diener, J. T., Kohn, A. E., Li, L., Erickson, C. A., Posey, D. J., & McDougle, C. J. (2009). Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger’s disorder: a 14-week, prospective, open-label study. Journal of child and adolescent psychopharmacology19(3), 265–274. https://doi.org/10.1089/cap.2008.093

Stigler, K. A., Potenza, M. N., Posey, D. J., & McDougle, C. J. (2004). Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management. Paediatric drugs6(1), 33–44. https://doi.org/10.2165/00148581-200406010-00003

Troost, PW., Lahuis, BE., Steenhuis, MP., Ketelaars, CEJ., Buitelaar, JK., Van Engeland, H., Scahill, L., Minderaa, RB., & Hoekstra, PJ. (2005). Long-term effects of risperidone in children with autism spectrum disorders: A placebo discontinuation study. Journal of the American Academy of Child and Adolescent Psychiatry44(11), 1137-1144. https://doi.org/10.1097/01.chi.0000177055.11229.76

Troost, P. W., Althaus, M., Lahuis, B. E., Buitelaar, J. K., Minderaa, R. B., & Hoekstra, P. J. (2006). Neuropsychological effects of risperidone in children with pervasive developmental disorders: a blinded discontinuation study. Journal of child and adolescent psychopharmacology16(5), 561–573. https://doi.org/10.1089/cap.2006.16.561

Troost, P. W., Steenhuis, M. P., Tuynman-Qua, H. G., Kalverdijk, L. J., Buitelaar, J. K., Minderaa, R. B., & Hoekstra, P. J. (2006). Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study. Journal of child and adolescent psychopharmacology16(5), 611–619. https://doi.org/10.1089/cap.2006.16.611

Vasa, R. A., Carroll, L. M., Nozzolillo, A. A., Mahajan, R., Mazurek, M. O., Bennett, A. E., Wink, L. K., & Bernal, M. P. (2014). A systematic review of treatments for anxiety in youth with autism spectrum disorders. Journal of autism and developmental disorders44(12), 3215–3229. https://doi.org/10.1007/s10803-014-2184-9

Volkmar, F. R., Lord, C., Bailey, A., Schultz, R. T., & Klin, A. (2004). Autism and pervasive developmental disorders. Journal of child psychology and psychiatry, and allied disciplines45(1), 135–170. https://doi.org/10.1046/j.0021-9630.2003.00317.x

Wasserman, S., Iyengar, R., Chaplin, W. F., Watner, D., Waldoks, S. E., Anagnostou, E., Soorya, L., & Hollander, E. (2006). Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. International clinical psychopharmacology21(6), 363–367. https://doi.org/10.1097/01.yic.0000224787.13782.0f

Wooltorton E. (2005). Suicidal ideation among children taking atomoxetine (Strattera). CMAJ : Canadian Medical Association journal = journal de l’Association medicale canadienne173(12), 1447. https://doi.org/10.1503/cmaj.051474

Yoon, Y., Wink, L. K., Pedapati, E. V., Horn, P. S., & Erickson, C. A. (2016). Weight Gain Effects of Second-Generation Antipsychotic Treatment in Autism Spectrum Disorder. Journal of child and adolescent psychopharmacology26(9), 822–827. https://doi.org/10.1089/cap.2016.0049

Zuddas, A., Ledda, M. G., Fratta, A., Muglia, P., & Cianchetti, C. (1996). Clinical effects of clozapine on autistic disorder. The American journal of psychiatry153(5), 738. https://doi.org/10.1176/ajp.153.5.738a

Pubmed search:

Goel, R., Hong, J. S., Findling, R. L., & Ji, N. Y. (2018). An update on pharmacotherapy of autism spectrum disorder in children and adolescents. International review of psychiatry (Abingdon, England), 30(1), 78–95. https://doi.org/10.1080/09540261.2018.1458706
Pharmacotherapy autism AND children

Kent, J. M., Kushner, S., Ning, X., Karcher, K., Ness, S., Aman, M., Singh, J., & Hough, D. (2013). Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study. Journal of autism and developmental disorders43(8), 1773–1783. https://doi.org/10.1007/s10803-012-1723-5
Goel et al (2018); Pharmacotherapy autism AND children

Ichikawa, H., Mikami, K., Okada, T., Yamashita, Y., Ishizaki, Y., Tomoda, A., Ono, H., Usuki, C., & Tadori, Y. (2017). Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study. Child psychiatry and human development48(5), 796–806. https://doi.org/10.1007/s10578-016-0704-x
Goel et al (2018); Pharmacotherapy autism AND children

Findling, R. L., McNamara, N. K., Gracious, B. L., O’Riordan, M. A., Reed, M. D., Demeter, C., & Blumer, J. L. (2004). Quetiapine in nine youths with autistic disorder. Journal of child and adolescent psychopharmacology14(2), 287–294. https://doi.org/10.1089/1044546041649129
Goel et al (2018); Pharmacotherapy autism AND children

Anderson, L. T., Campbell, M., Grega, D. M., Perry, R., Small, A. M., & Green, W. H. (1984). Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. The American journal of psychiatry141(10), 1195–1202. https://doi.org/10.1176/ajp.141.10.1195
Haloperidol autism AND children

Yoon, Y., Wink, L. K., Pedapati, E. V., Horn, P. S., & Erickson, C. A. (2016). Weight Gain Effects of Second-Generation Antipsychotic Treatment in Autism Spectrum Disorder. Journal of child and adolescent psychopharmacology26(9), 822–827. https://doi.org/10.1089/cap.2016.0049
Antipsychotics autism AND children

Stepanova, E., Dowling, S., Phelps, M., & Findling, R. L. (2017). Pharmacotherapy of emotional and behavioral symptoms associated with autism spectrum disorder in children and adolescents. Dialogues in clinical neuroscience19(4), 395–402. https://doi.org/10.31887/DCNS.2017.19.4/rfindling
Antipsychotics autism AND children

Vasa, R. A., Carroll, L. M., Nozzolillo, A. A., Mahajan, R., Mazurek, M. O., Bennett, A. E., Wink, L. K., & Bernal, M. P. (2014). A systematic review of treatments for anxiety in youth with autism spectrum disorders. Journal of autism and developmental disorders44(12), 3215–3229. https://doi.org/10.1007/s10803-014-2184-9
Citalopram autism AND children

McPheeters, M. L., Warren, Z., Sathe, N., Bruzek, J. L., Krishnaswami, S., Jerome, R. N., & Veenstra-Vanderweele, J. (2011). A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics127(5), e1312–e1321. https://doi.org/10.1542/peds.2011-0427
Citalopram autism AND children

Cooper, W. O., Callahan, S. T., Shintani, A., Fuchs, D. C., Shelton, R. C., Dudley, J. A., Graves, A. J., & Ray, W. A. (2014). Antidepressants and suicide attempts in children. Pediatrics133(2), 204–210. https://doi.org/10.1542/peds.2013-0923
Suicide antidepressants AND children

Pearson, D. A., Santos, C. W., Aman, M. G., Arnold, L. E., Casat, C. D., Mansour, R., Lane, D. M., Loveland, K. A., Bukstein, O. G., Jerger, S. W., Factor, P., Vanwoerden, S., Perez, E., & Cleveland, L. A. (2013). Effects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms. Journal of child and adolescent psychopharmacology23(5), 337–351. https://doi.org/10.1089/cap.2012.0096
Stimulants autism AND children

Smith, T., Aman, M. G., Arnold, L. E., Silverman, L. B., Lecavalier, L., Hollway, J., Tumuluru, R., Hyman, S. L., Buchan-Page, K. A., Hellings, J., Rice, R. R., Jr, Brown, N. V., Pan, X., & Handen, B. L. (2016). Atomoxetine and Parent Training for Children With Autism and Attention-Deficit/Hyperactivity Disorder: A 24-Week Extension Study. Journal of the American Academy of Child and Adolescent Psychiatry55(10), 868–876.e2. https://doi.org/10.1016/j.jaac.2016.06.015
Stimulants autism AND children

Reed, V. A., Buitelaar, J. K., Anand, E., Day, K. A., Treuer, T., Upadhyaya, H. P., Coghill, D. R., Kryzhanovskaya, L. A., & Savill, N. C. (2016). The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research. CNS drugs30(7), 603–628. https://doi.org/10.1007/s40263-016-0349-0
Suicide atomoxetine AND children

Roy, A., Roy, M., Deb, S., Unwin, G., & Roy, A. (2015). Are opioid antagonists effective in attenuating the core symptoms of autism spectrum conditions in children: a systematic review. Journal of intellectual disability research : JIDR59(4), 293–306. https://doi.org/10.1111/jir.12122
Naltrexon autism AND children

Chugani, D. C., Chugani, H. T., Wiznitzer, M., Parikh, S., Evans, P. A., Hansen, R. L., Nass, R., Janisse, J. J., Dixon-Thomas, P., Behen, M., Rothermel, R., Parker, J. S., Kumar, A., Muzik, O., Edwards, D. J., Hirtz, D., & Autism Center of Excellence Network (2016). Efficacy of Low-Dose Buspirone for Restricted and Repetitive Behavior in Young Children with Autism Spectrum Disorder: A Randomized Trial. The Journal of pediatrics170, 45–53.e534. https://doi.org/10.1016/j.jpeds.2015.11.033
Buspiron autism AND children

Mohammadi, M. R., Yadegari, N., Hassanzadeh, E., Farokhnia, M., Yekehtaz, H., Mirshafiee, O., & Akhondzadeh, S. (2013). Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study. Clinical neuropharmacology36(6), 179–184. https://doi.org/10.1097/WNF.0b013e3182a9339d
Amantadine autism AND children

    Het Kenniscentrum Kinder- en Jeugdpsychiatrie maakt gebruik van cookies voor analyse van het gebruik van deze website en om de website optimaal te laten werken. Uw bezoek blijft daarbij anoniem. Voor meer informatie, zie onze privacyverklaring

    De cookie-instellingen op deze website zijn ingesteld op 'toestaan cookies "om u de beste surfervaring mogelijk. Als u doorgaat met deze website te gebruiken zonder het wijzigen van uw cookie-instellingen of u klikt op "Accepteren" hieronder dan bent u akkoord met deze instellingen.

    Sluiten